Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 59 entries
Sorted by: Best Match Show Resources per page
Role of vaccination in the sustainability of healthcare systems.

Journal of market access & health policy

Largeron N, Lévy P, Wasem J, Bresse X.
PMID: 27123188
J Mark Access Health Policy. 2015 Aug 12;3. doi: 10.3402/jmahp.v3.27043. eCollection 2015.

The use of vaccines to prevent diseases in children, adults, and the elderly results in fewer medical visits, diagnostic tests, treatments, and hospitalisations, which leads to substantial savings in healthcare costs each year in Europe and elsewhere. Vaccines also...

Cite
Largeron N, Lévy P, Wasem J, et al. Role of vaccination in the sustainability of healthcare systems. J Mark Access Health Policy. 2015;3doi: 10.3402/jmahp.v3.27043.
Largeron, N., Lévy, P., Wasem, J., & Bresse, X. (2015). Role of vaccination in the sustainability of healthcare systems. Journal of market access & health policy, 3. https://doi.org/10.3402/jmahp.v3.27043
Largeron, Nathalie, et al. "Role of vaccination in the sustainability of healthcare systems." Journal of market access & health policy vol. 3 (2015). doi: https://doi.org/10.3402/jmahp.v3.27043
Largeron N, Lévy P, Wasem J, Bresse X. Role of vaccination in the sustainability of healthcare systems. J Mark Access Health Policy. 2015 Aug 12;3. doi: 10.3402/jmahp.v3.27043. eCollection 2015. PMID: 27123188; PMCID: PMC4802702.
Copy Download .nbib Format: NLM
Bioorthogonal Strategy for Bioprocessing of Specific-Site-Functionalized Enveloped Influenza-Virus-Like Particles.

Bioconjugate chemistry

Carvalho SB, Freire JM, Moleirinho MG, Monteiro F, Gaspar D, Castanho MARB, Carrondo MJT, Alves PM, Bernardes GJL, Peixoto C.
PMID: 27652605
Bioconjug Chem. 2016 Oct 19;27(10):2386-2399. doi: 10.1021/acs.bioconjchem.6b00372. Epub 2016 Oct 07.

Virus-like particles (VLPs) constitute a promising platform in vaccine development and targeted drug delivery. To date, most applications use simple nonenveloped VLPs as human papillomavirus or hepatitis B vaccines, even though the envelope is known to be critical to...

Cite
Carvalho SB, Freire JM, Moleirinho MG, et al. Bioorthogonal Strategy for Bioprocessing of Specific-Site-Functionalized Enveloped Influenza-Virus-Like Particles. Bioconjug Chem. 2016;27(10):2386-2399doi: 10.1021/acs.bioconjchem.6b00372.
Carvalho, S. B., Freire, J. M., Moleirinho, M. G., Monteiro, F., Gaspar, D., Castanho, M. A. R. B., Carrondo, M. J. T., Alves, P. M., Bernardes, G. J. L., & Peixoto, C. (2016). Bioorthogonal Strategy for Bioprocessing of Specific-Site-Functionalized Enveloped Influenza-Virus-Like Particles. Bioconjugate chemistry, 27(10), 2386-2399. https://doi.org/10.1021/acs.bioconjchem.6b00372
Carvalho, Sofia B, et al. "Bioorthogonal Strategy for Bioprocessing of Specific-Site-Functionalized Enveloped Influenza-Virus-Like Particles." Bioconjugate chemistry vol. 27,10 (2016): 2386-2399. doi: https://doi.org/10.1021/acs.bioconjchem.6b00372
Carvalho SB, Freire JM, Moleirinho MG, Monteiro F, Gaspar D, Castanho MARB, Carrondo MJT, Alves PM, Bernardes GJL, Peixoto C. Bioorthogonal Strategy for Bioprocessing of Specific-Site-Functionalized Enveloped Influenza-Virus-Like Particles. Bioconjug Chem. 2016 Oct 19;27(10):2386-2399. doi: 10.1021/acs.bioconjchem.6b00372. Epub 2016 Oct 07. PMID: 27652605; PMCID: PMC5080633.
Copy Download .nbib Format: NLM
Paths toward hepatitis B immunization in South Korea and Taiwan.

Clinical and experimental vaccine research

Chen TW.
PMID: 23858397
Clin Exp Vaccine Res. 2013 Jul;2(2):76-82. doi: 10.7774/cevr.2013.2.2.76. Epub 2013 Jul 03.

South Korea and Taiwan have had similar experiences of economic development in the post-war era. The two societies have also successfully overcome the threat of liver cancer by using mass hepatitis B vaccinations. However, to reach their current states,...

Cite
Chen TW. Paths toward hepatitis B immunization in South Korea and Taiwan. Clin Exp Vaccine Res. 2013;2(2):76-82doi: 10.7774/cevr.2013.2.2.76.
Chen, T. W. (2013). Paths toward hepatitis B immunization in South Korea and Taiwan. Clinical and experimental vaccine research, 2(2), 76-82. https://doi.org/10.7774/cevr.2013.2.2.76
Chen, Tzung-Wen. "Paths toward hepatitis B immunization in South Korea and Taiwan." Clinical and experimental vaccine research vol. 2,2 (2013): 76-82. doi: https://doi.org/10.7774/cevr.2013.2.2.76
Chen TW. Paths toward hepatitis B immunization in South Korea and Taiwan. Clin Exp Vaccine Res. 2013 Jul;2(2):76-82. doi: 10.7774/cevr.2013.2.2.76. Epub 2013 Jul 03. PMID: 23858397; PMCID: PMC3710927.
Copy Download .nbib Format: NLM
Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients.

Hepatitis monthly

Grzegorzewska AE.
PMID: 23326280
Hepat Mon. 2012 Nov;12(11):e7359. doi: 10.5812/hepatmon.7359. Epub 2012 Nov 14.

CONTEXT: Hepatitis B vaccination of hemodialysis patients is performed all over the world. There are also recommendations from world health organizations to vaccinate patients with chronic kidney disease (CKD) prior dialysis commencement, but the implementation of a hepatitis B...

Cite
Grzegorzewska AE. Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients. Hepat Mon. 2012;12(11):e7359doi: 10.5812/hepatmon.7359.
Grzegorzewska, A. E. (2012). Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients. Hepatitis monthly, 12(11), e7359. https://doi.org/10.5812/hepatmon.7359
Grzegorzewska, Alicja E. "Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients." Hepatitis monthly vol. 12,11 (2012): e7359. doi: https://doi.org/10.5812/hepatmon.7359
Grzegorzewska AE. Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients. Hepat Mon. 2012 Nov;12(11):e7359. doi: 10.5812/hepatmon.7359. Epub 2012 Nov 14. PMID: 23326280; PMCID: PMC3546461.
Copy Download .nbib Format: NLM
[Hepatitis B vaccines-history, achievements, challenges, and perspectives].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz

Gerlich WH.
PMID: 35015108
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Jan 11; doi: 10.1007/s00103-021-03484-w. Epub 2022 Jan 11.

The first experimental vaccinations against hepatitis B virus (HBV) were performed in 1970, even before the nature of the administered "Australia antigen" was known. Soon, it was realized that this antigen was the envelope protein (HBV surface antigen, HBsAg),...

Cite
Gerlich WH. Hepatitis-B-Impfstoffe – Geschichte, Erfolge, Herausforderungen und Perspektiven. [Hepatitis B vaccines-history, achievements, challenges, and perspectives]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022;doi: 10.1007/s00103-021-03484-w.
Gerlich, W. H. (2022). Hepatitis-B-Impfstoffe – Geschichte, Erfolge, Herausforderungen und Perspektiven. [Hepatitis B vaccines-history, achievements, challenges, and perspectives]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, . https://doi.org/10.1007/s00103-021-03484-w
Gerlich, Wolfram H. "Hepatitis-B-Impfstoffe – Geschichte, Erfolge, Herausforderungen und Perspektiven." [Hepatitis B vaccines-history, achievements, challenges, and perspectives]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz vol. (2022). doi: https://doi.org/10.1007/s00103-021-03484-w
Gerlich WH. Hepatitis-B-Impfstoffe – Geschichte, Erfolge, Herausforderungen und Perspektiven. [Hepatitis B vaccines-history, achievements, challenges, and perspectives]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Jan 11; doi: 10.1007/s00103-021-03484-w. Epub 2022 Jan 11. German. PMID: 35015108; PMCID: PMC8751463.
Copy Download .nbib Format: NLM
Hepatitis B Vaccine Non-Responders Show Higher Frequencies of CD24.

Frontiers in immunology

Körber N, Pohl L, Weinberger B, Grubeck-Loebenstein B, Wawer A, Knolle PA, Roggendorf H, Protzer U, Bauer T.
PMID: 34566969
Front Immunol. 2021 Sep 10;12:713351. doi: 10.3389/fimmu.2021.713351. eCollection 2021.

BACKGROUND: The cellular mechanisms involved in the lack of protective antibody response after hepatitis B vaccination are still rather unclear. Regulatory B cells (Breg) known as modulators of B-and T-cell responses may contribute to poor vaccine responsiveness. The current...

Cite
Körber N, Pohl L, Weinberger B, et al. Hepatitis B Vaccine Non-Responders Show Higher Frequencies of CD24. Front Immunol. 2021;12:713351doi: 10.3389/fimmu.2021.713351.
Körber, N., Pohl, L., Weinberger, B., Grubeck-Loebenstein, B., Wawer, A., Knolle, P. A., Roggendorf, H., Protzer, U., & Bauer, T. (2021). Hepatitis B Vaccine Non-Responders Show Higher Frequencies of CD24. Frontiers in immunology, 12713351. https://doi.org/10.3389/fimmu.2021.713351
Körber, Nina, et al. "Hepatitis B Vaccine Non-Responders Show Higher Frequencies of CD24." Frontiers in immunology vol. 12 (2021): 713351. doi: https://doi.org/10.3389/fimmu.2021.713351
Körber N, Pohl L, Weinberger B, Grubeck-Loebenstein B, Wawer A, Knolle PA, Roggendorf H, Protzer U, Bauer T. Hepatitis B Vaccine Non-Responders Show Higher Frequencies of CD24. Front Immunol. 2021 Sep 10;12:713351. doi: 10.3389/fimmu.2021.713351. eCollection 2021. PMID: 34566969; PMCID: PMC8461011.
Copy Download .nbib Format: NLM
12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial.

Vaccines

Han B, Liu W, Du J, Liu H, Zhao T, Yang S, Wang S, Zhang S, Liu B, Liu Y, Cui F.
PMID: 34960153
Vaccines (Basel). 2021 Nov 29;9(12). doi: 10.3390/vaccines9121407.

BACKGROUND: In initial studies, the immunogenicity and safety of hepatitis B vaccines in patients with diabetes has been assessed in China.METHODS: In six township health centers in Gansu Province, 232 diabetic patients and 77 healthy people were allocated to...

Cite
Han B, Liu W, Du J, et al. 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial. Vaccines (Basel). 2021;9(12)doi: 10.3390/vaccines9121407.
Han, B., Liu, W., Du, J., Liu, H., Zhao, T., Yang, S., Wang, S., Zhang, S., Liu, B., Liu, Y., & Cui, F. (2021). 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial. Vaccines, 9(12), . https://doi.org/10.3390/vaccines9121407
Han, Bingfeng, et al. "12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial." Vaccines vol. 9,12 (2021). doi: https://doi.org/10.3390/vaccines9121407
Han B, Liu W, Du J, Liu H, Zhao T, Yang S, Wang S, Zhang S, Liu B, Liu Y, Cui F. 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial. Vaccines (Basel). 2021 Nov 29;9(12). doi: 10.3390/vaccines9121407. PMID: 34960153; PMCID: PMC8705985.
Copy Download .nbib Format: NLM
Host Genetic Determinants of Hepatitis B Virus Infection.

Frontiers in genetics

Zhang Z, Wang C, Liu Z, Zou G, Li J, Lu M.
PMID: 31475028
Front Genet. 2019 Aug 13;10:696. doi: 10.3389/fgene.2019.00696. eCollection 2019.

Chronic hepatitis B virus (HBV) infection is still a major health problem worldwide. Recently, a great number of genetic studies based on single nucleotide polymorphisms (SNPs) and genome-wide association studies have been performed to search for host determinants of...

Cite
Zhang Z, Wang C, Liu Z, et al. Host Genetic Determinants of Hepatitis B Virus Infection. Front Genet. 2019;10:696doi: 10.3389/fgene.2019.00696.
Zhang, Z., Wang, C., Liu, Z., Zou, G., Li, J., & Lu, M. (2019). Host Genetic Determinants of Hepatitis B Virus Infection. Frontiers in genetics, 10696. https://doi.org/10.3389/fgene.2019.00696
Zhang, Zhenhua, et al. "Host Genetic Determinants of Hepatitis B Virus Infection." Frontiers in genetics vol. 10 (2019): 696. doi: https://doi.org/10.3389/fgene.2019.00696
Zhang Z, Wang C, Liu Z, Zou G, Li J, Lu M. Host Genetic Determinants of Hepatitis B Virus Infection. Front Genet. 2019 Aug 13;10:696. doi: 10.3389/fgene.2019.00696. eCollection 2019. PMID: 31475028; PMCID: PMC6702792.
Copy Download .nbib Format: NLM
Hepatitis B Vaccines.

The Journal of infectious diseases

Pattyn J, Hendrickx G, Vorsters A, Van Damme P.
PMID: 34590138
J Infect Dis. 2021 Sep 30;224:S343-S351. doi: 10.1093/infdis/jiaa668.

Hepatitis B is caused by the hepatitis B virus (HBV), which infects the liver and may lead to chronic liver disease, including cirrhosis and hepatocellular carcinoma. HBV represents a worldwide public health problem, causing major morbidity and mortality. Affordable,...

Cite
Pattyn J, Hendrickx G, Vorsters A, et al. Hepatitis B Vaccines. J Infect Dis. 2021;224:S343-S351doi: 10.1093/infdis/jiaa668.
Pattyn, J., Hendrickx, G., Vorsters, A., & Van Damme, P. (2021). Hepatitis B Vaccines. The Journal of infectious diseases, 224S343-S351. https://doi.org/10.1093/infdis/jiaa668
Pattyn, Jade, et al. "Hepatitis B Vaccines." The Journal of infectious diseases vol. 224 (2021): S343-S351. doi: https://doi.org/10.1093/infdis/jiaa668
Pattyn J, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B Vaccines. J Infect Dis. 2021 Sep 30;224:S343-S351. doi: 10.1093/infdis/jiaa668. PMID: 34590138; PMCID: PMC8482019.
Copy Download .nbib Format: NLM
[Hepatitis B vaccines-history, achievements, challenges, and perspectives].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz

Gerlich WH.
PMID: 35015108
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Jan 11; doi: 10.1007/s00103-021-03484-w. Epub 2022 Jan 11.

The first experimental vaccinations against hepatitis B virus (HBV) were performed in 1970, even before the nature of the administered "Australia antigen" was known. Soon, it was realized that this antigen was the envelope protein (HBV surface antigen, HBsAg),...

Cite
Gerlich WH. Hepatitis-B-Impfstoffe – Geschichte, Erfolge, Herausforderungen und Perspektiven. [Hepatitis B vaccines-history, achievements, challenges, and perspectives]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022;doi: 10.1007/s00103-021-03484-w.
Gerlich, W. H. (2022). Hepatitis-B-Impfstoffe – Geschichte, Erfolge, Herausforderungen und Perspektiven. [Hepatitis B vaccines-history, achievements, challenges, and perspectives]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, . https://doi.org/10.1007/s00103-021-03484-w
Gerlich, Wolfram H. "Hepatitis-B-Impfstoffe – Geschichte, Erfolge, Herausforderungen und Perspektiven." [Hepatitis B vaccines-history, achievements, challenges, and perspectives]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz vol. (2022). doi: https://doi.org/10.1007/s00103-021-03484-w
Gerlich WH. Hepatitis-B-Impfstoffe – Geschichte, Erfolge, Herausforderungen und Perspektiven. [Hepatitis B vaccines-history, achievements, challenges, and perspectives]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Jan 11; doi: 10.1007/s00103-021-03484-w. Epub 2022 Jan 11. German. PMID: 35015108.
Copy Download .nbib Format: NLM
Hepatitis B vaccines.

Infectious disease clinics of North America

Yu AS, Cheung RC, Keeffe EB.
PMID: 16527647
Infect Dis Clin North Am. 2006 Mar;20(1):27-45. doi: 10.1016/j.idc.2006.01.004.

Immunization is the most effective way to prevent transmission of HBV and, hence, the development of acute or chronic hepatitis B. The national strategy to eliminate transmission of the virus in the United States includes vaccination of all newborn...

Cite
Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. Infect Dis Clin North Am. 2006;20(1):27-45doi: 10.1016/j.idc.2006.01.004.
Yu, A. S., Cheung, R. C., & Keeffe, E. B. (2006). Hepatitis B vaccines. Infectious disease clinics of North America, 20(1), 27-45. https://doi.org/10.1016/j.idc.2006.01.004
Yu, Andy S, et al. "Hepatitis B vaccines." Infectious disease clinics of North America vol. 20,1 (2006): 27-45. doi: https://doi.org/10.1016/j.idc.2006.01.004
Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. Infect Dis Clin North Am. 2006 Mar;20(1):27-45. doi: 10.1016/j.idc.2006.01.004. PMID: 16527647.
Copy Download .nbib Format: NLM
Thimerosal-containing hepatitis B vaccination and the risk for diagnosed specific delays in development in the United States: a case-control study in the vaccine safety datalink.

North American journal of medical sciences

Geier DA, Kern JK, Hooker BS, King PG, Sykes LK, Geier MR.
PMID: 25489565
N Am J Med Sci. 2014 Oct;6(10):519-31. doi: 10.4103/1947-2714.143284.

BACKGROUND: Within the first 3 years of life, the brain develops rapidly. Its development is characterized by critical developmental periods for speech, vision, hearing, language, balance, etc.; and alteration in any of the processes occurring in those critical periods...

Cite
Geier DA, Kern JK, Hooker BS, et al. Thimerosal-containing hepatitis B vaccination and the risk for diagnosed specific delays in development in the United States: a case-control study in the vaccine safety datalink. N Am J Med Sci. 2014;6(10):519-31doi: 10.4103/1947-2714.143284.
Geier, D. A., Kern, J. K., Hooker, B. S., King, P. G., Sykes, L. K., & Geier, M. R. (2014). Thimerosal-containing hepatitis B vaccination and the risk for diagnosed specific delays in development in the United States: a case-control study in the vaccine safety datalink. North American journal of medical sciences, 6(10), 519-31. https://doi.org/10.4103/1947-2714.143284
Geier, David A, et al. "Thimerosal-containing hepatitis B vaccination and the risk for diagnosed specific delays in development in the United States: a case-control study in the vaccine safety datalink." North American journal of medical sciences vol. 6,10 (2014): 519-31. doi: https://doi.org/10.4103/1947-2714.143284
Geier DA, Kern JK, Hooker BS, King PG, Sykes LK, Geier MR. Thimerosal-containing hepatitis B vaccination and the risk for diagnosed specific delays in development in the United States: a case-control study in the vaccine safety datalink. N Am J Med Sci. 2014 Oct;6(10):519-31. doi: 10.4103/1947-2714.143284. PMID: 25489565; PMCID: PMC4215490.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 59 entries